spacer.png, 0 kB
TimTec and Collaborative Drug Discovery PDF Print E-mail
Press Releases

TimTec and Collaborative Drug Discovery Team Up to Provide Chemically Searchable Natural Products and Derivatives Available to the Scientific Community.

TimTec LLC., the international distributor of synthetic organic and natural compounds, and Collaborative Drug Discovery, Inc. (CDD), the community based research information management enterprise, announced today that the CDD web-based software now hosts TimTec’s Natural Product Library and Natural Derivatives Library. The TimTec natural product and derivative compounds are now available as a structure searchable database in the CDD Web2.0 collaborative research information system.


The CDD-TimTec Natural Products Library (NPL-480) and Natural Derivatives Library (NDL-3000) databases comprise almost 3,500 compounds available from TimTec. NPL-480 is a new library of 480 natural compounds composed of pure natural products as lead identifying materials. NDL-3000 elaborates on structural variety of pure natural compounds and includes synthetic compounds and synthetically modified pure natural compounds including, but not limited to, alkaloids, natural phenols, nucleoside analogs, carbohydrates, purines, pyrimidines, flavonoids, steroidal compounds and natural amino acids.

“The growing number of research institutions world-wide now investigating natural products will buoy the discovery of novel chemistry leading to a wealth of therapeutic breakthroughs,” said Dr. Barry Bunin, President of Collaborative Drug Discovery. “It’s natural that TimTec’s laboratories complement CDD’s academic partners in natural products research with a unique commercial source of natural products and diverse derivatives.”

“Beyond our successful compounds libraries, chemical software and drug discovery services, TimTec immediately appreciates the unique advantage and elegance of the CDD system to share our natural product compounds with the growing CDD community,” said Dr. Murat Niyazymbetov founder and President of TimTec.

The TimTec databases join 14 other publicly available data sources in the CDD system with chemical and biological data for over 42,000 agents including:

* 1,700 FDA approved drugs with indications and sponsors
* Over 15,000 compounds with Malaria assay data from 5 public data sources
* More than 850 compounds with Tuberculosis antibacterial activity information
* Over 47,000 Ki values against 699 GPCR targets from the NIMH Psychoactive Drug Screening Program (PDSP) Database
* 25,000 plus compounds available for purchase

About TimTec LLC.
TimTec LLC. - http://www.timtec.net - is a privately held company located in Newark Delaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. The company has developed strong in-house expertise assembling general and targeted library collections for variety of research purposes. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs.

For further information please contact:

Barry Bunin, Ph.D.
President & CEO
Collaborative Drug Discovery (CDD)
1818 Gilbreth Road, Suite 220
Burlingame, CA 94010
650-204-3084
info(at)collaborativedrug.com

Kay Denisova
Business Development
TimTec LLC.
Harmony Business Park Building 301-A
Newark, DE 19711
Tel 302 292 8500
Fax 302 292 8520
info(at)timtec.net
http://www.timtec.net

< Prev
 

Latest News and Articles

Drug Discovery News

  • Alzheimer’s Study Leads To Better Drug For Infections
    Research into Alzheimer’s disease seems an unlikely approach to yield a better way to fight urinary tract infections (UTIs), but that’s what scientists at Washington University School of Medicine in St. Louis and elsewhere recently reported. One element links the disparate areas of research: amyloids, which are fibrous, sticky protein aggregates. [...]
  • University of California, San Francisco, Researcher Receives ASBMB-Merck Award
    Bethesda, MD, December 12, 2009 –(PR.com)– James A. Wells, professor and chairman of the department pharmaceutical chemistry at the University of California, San Francisco, and director of UCSF’s small molecule discovery center, has been named the winner of the 2010 American Society for Biochemistry and Molecular Biology-Merck Award for his [...]
  • Techne accelerates sample concentration
    The Techne Sample Concentrator provides fast solvent or diluent evaporation without sample loss when used with one of the company’s Dri-Block heaters. The height-adjustable head of the concentrator delivers a flow of inert gas that removes evaporated solvent from the surface of solutions in tubes or 96-well plates. Traditional methods of reducing [...]
  • Potent Novel Tool For Combating Autoimmune Diseases And Leukemia
    A study carried out by the scientists at the Scripps Research Institute illustrated a novel, highly practical strategy for identifying molecules that avert a particular form of immune cells from launching assaults on their host. These findings have added a potent new-fangled tool to the ongoing investigation for probable treatments [...]
  • Karwar scientist’s theory to ‘weed’ out CO2
    KARWAR: While representatives of 192 countries are engaged in climate change debates at Copenhagen, Dr Ullas Naik, a marine scientist at the department of marine biology, at Karnatak University’s PG Centre, here has suggested the unassuming sea weed as a possible cure to the planet’s ills.Calling for the scientific culture [...]
  • Hi-tech microscopes make androgen therapy ‘personal’
    HOUSTON — (December 9, 2009) — On rare occasions, an infant is born with outward appearance of a female but the XY chromosomes of a male. If the child has a normal Y chromosome — the chromosome responsible for testicular development — the condition is known as androgen insensitivity syndrome. Experts estimate [...]
  • 2009: The Year That Was For Pfizer
    (RTTNews) - True to expectations, Jeffrey Kindler, the CEO of Pfizer Inc. (PFE | Quote | Chart | News | PowerRating), scripted a new playbook for the drug giant in 2009, accelerating the process of transformation by clinching the largest pharmaceutical [...]
  • Model for powerful flu fighters from existing drugs
    Computer compatibility tests might help flu-fighting drugs find their groove. A pandemic of the H1N1 swine flu virus has health officials worried that the virus could develop resistance to drugs such as Tamiflu used to treat infected people. A new computerized screening method could help find new or already existing drugs that [...]
  • Therasis Obtains $12 Million From Tilocor in Series A Round
    GA_googleCreateDomIframe(’google_ads_div_Press336′ ,’Press336′); GA_googleFillSlot(”Press160″); GA_googleCreateDomIframe(’google_ads_div_Press160′ ,’Press160′); NEW YORK, NY — 12/08/09 [...]
  • InformexUSA 2010
    InformexUSA has become the leading resource for buyers and sellers of high-value chemistry for a broad range of applications. Today’s pharmaceutical innovators, agrochemical product makers, electronic materials producers and other manufacturers that come to Informex find what they need for business success: mainly new ideas that make a difference, and qualified companies with production assets [...]
spacer.png, 0 kB